-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $48

Benzinga·08/31/2026 18:01:39
Listen to the news
Goldman Sachs analyst Salveen Richter initiates coverage on Braveheart Bio (NASDAQ:BRVE) with a Buy rating and announces Price Target of $48.